Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1

Eric J Lowe, Anne F Reilly, Megan S Lim, Thomas G Gross, Lauren Saguilig, Donald A Barkauskas, Rui Wu, Sarah Alexander, Catherine M Bollard, Eric J Lowe, Anne F Reilly, Megan S Lim, Thomas G Gross, Lauren Saguilig, Donald A Barkauskas, Rui Wu, Sarah Alexander, Catherine M Bollard

Abstract

Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) relapse. Although brentuximab vedotin has demonstrated excellent activity in ALCL, it has not been used for newly diagnosed patients. Children's Oncology Group (COG) trial ANHL12P1 determined the toxicity and efficacy of brentuximab vedotin with chemotherapy in children with newly diagnosed nonlocalized anaplastic large cell lymphoma kinase (ALK)+/CD30+ ALCL. From 2013 to 2017, 68 children with ALK+ ALCL were enrolled and received brentuximab vedotin. All patients received 5-day prophase, followed by 6 cycles of chemotherapy. Brentuximab vedotin was given on day 1 of each of the 6 cycles. Of the 67 patients eligible for toxicity evaluation, 66 completed all 6 cycles of chemotherapy, resulting in 399 evaluable cycles. There were no toxic deaths, no case of progressive multifocal leukoencephalopathy syndrome, and no case of grade 3 or 4 neuropathy. The 2-year event-free survival (EFS) was 79.1% (95% confidence interval [CI], 67.2-87.1). The 2-year overall survival (OS) was 97.0% (95% CI, 88.1-99.2). Fourteen patients relapsed. Eleven of 14 (79%) relapses occurred within 10 months of diagnosis; only 1 patient (1.5%) relapsed during therapy. Quantitative reverse transcription polymerase chain reaction for NPM-ALK at baseline (minimal disseminated disease) demonstrated prognostic value for EFS (P = .0004). Overall, the addition of brentuximab vedotin to standard chemotherapy does not add significant toxicity or alter the desired interval between cycles. The addition of brentuximab vedotin prevented relapses during therapy, and the OS and EFS estimates compare favorably with results obtained using conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01979536.

© 2021 by The American Society of Hematology.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
EFS (2-year, 79.1%; 95% CI, 67.2-87.1) and OS (2-year, 97%; 95% CI, 88.1-99.2) for newly diagnosed patients with ALK+ ALCL in arm BV of ANHL12P1.
Figure 2.
Figure 2.
EFS and OS of newly diagnosed patients with ALK+ALCL in arm BV of ANHL12P1, according to baseline MDD (n = 57; MDD negative = 38, MDD positive = 19). qRT-PCR with a cutoff >10 copies of NPM-ALK per 104 copies of ABL was used to define MDD positivity.

References

    1. Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30(6):509-519.
    1. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med. 1996;334(19):1238-1248.
    1. Seidemann K, Tiemann M, Schrappe M, et al. . Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-3706.
    1. Stein H, Mason DY, Gerdes J, et al. . The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-858.
    1. Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
    1. Perkins SL, Pickering D, Lowe EJ, et al. . Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol. 2005;131(5):624-627.
    1. Turner SD, Lamant L, Kenner L, Brugières L. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol. 2016;173(4):560-572.
    1. Alexander S, Kraveka JM, Weitzman S, et al. . Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children’s oncology group. Pediatr Blood Cancer. 2014;61(12):2236-2242.
    1. Brugières L, Deley MC, Pacquement H, et al. . CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591-3598.
    1. Brugières L, Le Deley MC, Rosolen A, et al. . Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897-903.
    1. Laver JH, Kraveka JM, Hutchison RE, et al. . Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-547.
    1. Le Deley MC, Rosolen A, Williams DM, et al. . Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987-3993.
    1. Lowe EJ, Sposto R, Perkins SL, et al. ; Children’s Cancer Group Study 5941 . Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52(3):335-339.
    1. Pillon M, Gregucci F, Lombardi A, et al. ; NHL-Committee of the Italian Association of Pediatric Hematology and Oncology (AIEOP) . Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer. 2012;59(5):828-833.
    1. Rosolen A, Pillon M, Garaventa A, et al. . Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104(10):2133-2140.
    1. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR; United Kingdom Children’s Cancer Study Group . Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812-820.
    1. Woessmann W, Peters C, Lenhard M, et al. . Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-182.
    1. Woessmann W, Zimmermann M, Lenhard M, et al. . Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065-3071.
    1. Knörr F, Brugières L, Pillon M, et al. ; European Inter-Group for Childhood Non-Hodgkin Lymphoma . Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-Relapse Trial. J Clin Oncol. 2020;38(34):3999-4009.
    1. Brugières L, Pacquement H, Le Deley MC, et al. . Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-5061.
    1. Pro B, Advani R, Brice P, et al. . Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [published correction appears in Blood; 2018;132(4):458-459]. Blood. 2017;130(25):2709-2717.
    1. Locatelli F, Mauz-Koerholz C, Neville K, et al. . Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-e461.
    1. Pro B, Advani R, Brice P, et al. . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
    1. Lamant L, Meggetto F, al Saati T, et al. . High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin’s disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996;87(1):284-291.
    1. Damm-Welk C, Busch K, Burkhardt B, et al. . Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110(2):670-677.
    1. Younes A, Connors JM, Park SI, et al. . Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348-1356.
    1. Horwitz S, O’Connor OA, Pro B, et al. ; ECHELON-2 Study Group . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240.
    1. Brugières L, Quartier P, Le Deley MC, et al. . Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11(1):53-58.
    1. Mussolin L, Le Deley MC, Carraro E, et al. . Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the International ALCL99 Trial. Cancers (Basel). 2020;12(10):2747.
    1. Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers (Basel). 2018;10(4):99.
    1. Gambacorti-Passerini C, Orlov S, Zhang L, et al. . Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study. Am J Hematol. 2018;93(5):607-614.
    1. Mossé YP, Voss SD, Lim MS, et al. . Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215-3221.
    1. Waight AB, Bargsten K, Doronina S, Steinmetz MO, Sussman D, Prota AE. Structural basis of microtubule destabilization by potent auristatin anti-mitotics. PLoS One. 2016;11(8):e0160890.
    1. Alley S, Oflazoglu E, Jonas M, et al. . Abstract #3234: Antibody-targeted delivery of auristatin using SGN-35 leads to one to two logs greater intratumoral auristatin concentrations than non-targeted therapy. Cancer Res. 2009;69(9 suppl):3234.
    1. Wrobel G, Mauguen A, Rosolen A, et al. ; European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL) . Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56(7):1071-1077.
    1. Damm-Welk C, Kutscher N, Zimmermann M, et al. . Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma. Haematologica. 2020;105(8):2141-2149.
    1. Iijima-Yamashita Y, Mori T, Nakazawa A, et al. . Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. Int J Hematol. 2018;107(2):244-250.
    1. Lamant L, McCarthy K, d’Amore E, et al. . Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-4676.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren